

Additional disclosures

Store network

Retail operations – store network history

Open at 31 December	2025	2024	2023	2022	2021
BUNNINGS GROUP					
Bunnings Warehouse	287	286	286	283	280
Bunnings smaller formats	66	65	65	68	69
Bunnings Trade Centres	28	30	31	31	30
Tool Kit Depot	16	16	14	13	9
Beaumont Tiles ¹	110	113	117	116	114
Total Bunnings Group	507	510	513	511	502
KMART GROUP					
Kmart	271	270	270	269	270
K hub	53	53	55	56	56
Target	122	124	124	126	134
Total Kmart Group²	446	447	449	451	460
OFFICEWORKS					
Officeworks	175	172	169	166	167
WESFARMERS HEALTH					
Priceline ³	68	69	73	83	n.r.
Priceline Pharmacy ⁴	424	415	400	388	n.r.
Banner brand pharmacies ⁵	155	97	99	91	n.r.
SILK Laser ⁶	153	155	146	-	n.r.
Clear Skincare	34	49	88	96	n.r.
Total Wesfarmers Health	834	785	806	658	n.r.

¹ Includes both company-owned and franchise stores.

² Excludes Anko stores that operate in the Philippines through a joint venture.

³ Refers to company-owned stores and includes atomica.

⁴ Refers to franchise stores and includes InstantScripts Pharmacy Health Hub.

⁵ Includes Soul Pattinson Chemist, Pharmacist Advice and Pharmacy 4 Less banner brands operated by independent pharmacies.

⁶ Includes company-owned, jointly-owned and franchise clinics.

Additional disclosures

Five-year history – financial performance and key metrics

Group financial performance

Half-year ended 31 December ¹ (\$m)	2025	2024	2023	2022	2021
Summarised income statement					
Revenue	24,212	23,490	22,673	22,558	17,758
EBIT (after interest on lease liabilities)	2,347	2,176	2,081	2,053	1,796
Other finance costs	(66)	(83)	(81)	(62)	(48)
Income tax expense	(678)	(626)	(575)	(607)	(535)
NPAT	1,603	1,467	1,425	1,384	1,213
Summarised balance sheet					
Total assets ²	28,846	27,710	27,291	27,608	25,231
Total liabilities ²	20,990	18,737	18,872	19,514	17,488
Net assets	7,856	8,973	8,419	8,094	7,743
Net debt / (cash)	4,983	3,990	3,888	4,674	2,863
Summarised cash flow statement					
Operating cash flows	2,491	2,575	2,898	1,971	1,556
Add/(less): Net capital expenditure	(311)	(555)	(570)	(578)	(405)
Add/(less): Other investing cash flows	565	5	(316)	(28)	(202)
Add/(less): Total investing cash flows	254	(550)	(886)	(606)	(607)
Free cash flows	2,745	2,025	2,012	1,365	949
Add/(less): Financing cash flows	(2,654)	(2,373)	(1,881)	(1,438)	(3,349)
Net increase/(decrease) in cash	91	(348)	131	(73)	(2,400)
Distributions to shareholders (cents per share)					
Interim ordinary dividend	102	95	91	88	80
Key performance metrics					
Earnings per share (cps)	141.4	129.4	125.8	122.3	107.3
Operating cash flow per share (cps)	219.7	227.1	255.8	174.1	137.5
Cash realisation ratio (%)	99	108	126	89	79
Return on equity (R12) (%)	35.2	31.2	31.4	32.8	24.8
Return on equity (excluding sig. items) ³ (R12) (%)	32.7	31.2	31.4	32.8	24.8
Net tangible asset backing per share (\$ per share) ²	2.57	3.39	2.98	3.01	3.35

¹ See Additional Disclosures on page 50 for relevant definitions.

² 2022 has been restated to reflect the adjustments to the provisional acquisition accounting for Australian Pharmaceuticals Industries Pty Ltd.

³ 2025 excludes \$273 million in post-tax significant items (\$279 million pre-tax) recorded in the second half of the 2025 financial year, relating to the gain on sale of Coregas, profit on the wind up of the BPI property structure and costs associated with the wind down and transition of Catch.

Additional disclosures

Five-year history – financial performance and key metrics

Divisional key performance metrics

Half-year ended 31 December (\$m)	2025	2024	2023	2022	2021
Bunnings Group					
Revenue	10,713	10,280	9,963	9,792	9,209
EBITDA ¹	1,873	1,799	1,748	1,721	1,677
Depreciation and amortisation	(408)	(411)	(408)	(387)	(362)
Interest on lease liabilities	(77)	(66)	(58)	(56)	(56)
EBT ¹	1,388	1,322	1,282	1,278	1,259
EBT margin ¹ (%)	13.0	12.9	12.9	13.1	13.7
ROC ¹ (R12) (%)	70.8	71.5	65.8	70.7	79.0
Capital expenditure (cash basis)	229	234	135	226	196
Total sales growth (%)	4.0	3.1	1.7	6.3	1.7
Total store sales growth ² (%)	4.1	3.5	1.9	5.1	1.0
Store-on-store sales growth ² (%)	4.2	3.4	1.2	2.8	1.5
Digital sales ³ (%)	7.6	6.3	5.1	4.4	6.6
Safety (R12) (TRIFR)	13.5	14.4	15.9	16.9	12.5
Scope 1 and 2 (market-based) emissions (kt)	8	17	27	31	54
Scope 1 and 2 (location-based) emissions (kt)	80	81	86	92	107
Kmart Group					
Revenue	6,307	6,108	5,986	5,714	4,605
EBITDA	992	947	895	765	513
Depreciation and amortisation	(259)	(262)	(252)	(250)	(247)
Interest on lease liabilities	(50)	(41)	(42)	(40)	(44)
EBT	683	644	601	475	222
EBT margin (%)	10.8	10.5	10.0	8.3	4.8
ROC (R12) (%)	69.8	65.9	58.8	43.3	34.7
Capital expenditure (cash basis)	119	66	85	62	62
Total sales growth ⁴ (%)	3.2	2.0	5.0	24.5	(10.2)
Comparable sales growth ⁴ (%)	2.8	1.9	5.3	13.7	(2.2)
Digital sales ⁵ (%)	10.3	9.7	9.5	9.4	17.5
Safety (R12) (TRIFR)	6.7	6.1	7.3	7.0	8.6
Scope 1 and 2 (market-based) emissions (kt)	1	86	91	115	120
Scope 1 and 2 (location-based) emissions (kt)	103	105	112	119	135

¹ Includes net property contribution for 2025 of \$(1) million; 2024 of \$(1) million; 2023 of nil; 2022 of \$35 million; and 2021 of \$41 million.

² Includes cash, trade and online sales, excludes property income and sales related to Trade Centres, Frame & Truss, Tool Kit Depot and Beaumont Tiles. Store-on-store sales growth in 2023, 2022 and 2021 excludes stores in months that were impacted by extended periods of temporary closure in New South Wales, Australian Capital Territory, Victoria and New Zealand.

³ Digital sales includes online sales, app sales and marketplace sales expressed as a share of total sales including marketplace.

⁴ Based on retail periods (rather than Gregorian reporting). Comparable store sales recognise layby sales at point of deposit. Total sales recognise layby sales in accordance with the guidelines set by the Australian Accounting Standards. Comparable growth calculation in 2023, 2022 and 2021 excludes stores that were temporarily closed due to COVID-19 restrictions for the duration of the closure period, where the closure period was longer than two weeks.

⁵ Digital sales includes online sales and marketplace sales expressed as a share of total sales including marketplace.

Additional disclosures

Five-year history – financial performance and key metrics

Divisional key performance metrics (continued)

Half-year ended 31 December (\$m)	2025	2024	2023	2022	2021
Chemicals, Energy and Fertilisers					
Chemicals revenue ^{1,2}	739	704	628	860	642
Energy revenue ¹	203	260	262	265	252
Fertilisers revenue ¹	229	246	215	277	183
Total revenue ¹	1,171	1,210	1,105	1,402	1,077
EBITDA	291	255	229	372	262
Depreciation and amortisation	(81)	(77)	(56)	(48)	(43)
Interest on lease liabilities	(1)	(1)	(1)	-	(1)
EBT	209	177	172	324	218
ROC (R12, %)	11.9	12.8	16.2	23.0	19.6
ROC (R12) (%) (excluding ALM)	31.7	32.5	32.9	40.3	32.2
Capital expenditure (cash basis) ³	157	204	255	272	238
Safety (R12) (TRIFR)	2.7	4.6	3.7	3.0	4.2
Scope 1 and 2 (market-based) emissions ⁴ (kt)	383	421	419	433	370
Scope 1 and 2 (location-based) emissions ⁴ (kt)	389	426	417	433	373
External sales volumes⁵ ('000 tonnes)					
Chemicals ²	609	571	584	562	565
LPG & LNG	97	101	104	108	109
Fertilisers	310	396	302	248	286
Officeworks					
Revenue	1,842	1,760	1,681	1,651	1,580
EBITDA	152	166	161	152	142
Depreciation and amortisation	(74)	(70)	(67)	(62)	(55)
Interest on lease liabilities	(10)	(9)	(8)	(5)	(5)
EBT	68	87	86	85	82
EBT margin (%)	3.7	4.9	5.1	5.1	5.2
ROC (R12) (%)	15.6	18.3	18.3	17.3	19.6
Capital expenditure (cash basis)	56	29	28	26	28
Total sales growth (%)	4.7	4.7	1.8	4.6	3.7
Online penetration (%)	35.1	36.0	34.7	34.5	46.0
Safety (R12) (TRIFR)	7.0	7.4	4.6	6.1	5.5
Scope 1 and 2 (market-based) emissions (kt)	0	11	12	14	15
Scope 1 and 2 (location-based) emissions (kt)	14	14	14	15	18

¹ Excludes intra-division sales.

² 2025 Chemicals revenue and external sales volumes include the sale of approximately 96kt of spodumene concentrate (2024: 80kt).

³ Includes WesCEF's share of capital expenditure for the development of the Covalent lithium project in 2025 of \$18 million, 2024 of \$110 million, 2023 of \$164 million, 2022 of \$204 million, and 2021 of \$139 million. 2025, 2024, 2023, 2022 and 2021 include capitalised interest of \$17 million, \$14 million, \$13 million, \$21 million and \$16 million respectively. Includes capital expenditure made prior to the final investment decision in 2020 of \$15 million.

⁴ 2022 Scope 1 and Scope 2 emissions include the impact of the scheduled ammonia plant shutdown.

⁵ External sales exclude AN volumes transferred between Chemicals and Fertilisers business segments.

Additional disclosures

Five-year history – financial performance and key metrics

Divisional key performance metrics (continued)

Half-year ended 31 December (\$m)	2025	2024	2023	2022	2021
Wesfarmers Health					
Revenue	3,276	3,022	2,774	2,778	n.r.
EBITDA ¹	82	68	66	66	n.r.
Depreciation and amortisation	(39)	(37)	(37)	(36)	n.r.
Interest on lease liabilities	(5)	(3)	(2)	(3)	n.r.
EBT ¹	38	28	27	27	n.r.
EBT margin ¹ (%)	1.2	0.9	1.0	1.0	n.r.
ROC ¹ (R12) (%)	4.2	3.1	3.5	n.r.	n.r.
Capital expenditure (cash basis)	35	26	20	20	n.r.
Safety (R12) (TRIFR)	4.5	3.9	5.9	n.r.	n.r.
Scope 1 and 2 (market-based) emissions (kt)	3	6	5	7	n.r.
Scope 1 and 2 (location-based) emissions (kt)	4	5	5	7	n.r.
Industrial and Safety²					
Revenue	869	990	1,009	978	944
EBITDA ³	67	88	92	89	80
Depreciation and amortisation	(33)	(41)	(41)	(40)	(37)
Interest on lease liabilities	(2)	(2)	(2)	(2)	(2)
EBT ³	32	45	49	47	41
EBT margin ³ (%)	3.7	4.5	4.9	4.8	4.3
ROC ³ (R12) (%)	9.1	8.0	7.9	8.1	6.5
Capital expenditure (cash basis)	19	28	42	31	25
Safety (R12) (TRIFR)	2.6	1.7	3.2	4.0	3.1
Scope 1 and 2 (market-based) emissions (kt)	4	13	13	14	14
Scope 1 and 2 (location-based) emissions (kt)	4	12	13	13	14

¹ 2025 includes \$7 million of amortisation expenses relating to assets recognised as part of the acquisitions of API, InstantScripts, SILK and SiSU (2024: \$9 million), and 2024 includes \$4 million of restructuring costs.

² 2021 to 2024 include results from Coregas prior to its divestment on 1 July 2025. 2021 and 2022 include results from Greencap prior to its divestment on 1 August 2022.

³ 2024 includes \$7 million of restructuring costs.